TriangleHEALTH PROFESSIONAL · SOURCE READING
Immunotherapeutic Approaches for Relapsed or Refractory ALL
Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Relapsed Childhood ALL
Immunotherapeutic approaches for the treatment of relapsed or refractory ALL include monoclonal antibody therapy and CAR T-cell therapy.
Continue within this section
Preserved source evidence · Not medical advice